Safe handling of highly potent molecules is complex, and the associated regulatory requirements are growing. As a result, pharmaceutical companies recognize the importance of selecting the right partner for the development.
A panel of experts from PCI Pharma Services and three Life Sciences companies discuss challenges and opportunities related to the development, clinical phases and commercialization of biologics, offering insights on how to improve sponsor-CDMO
Oncology clinical trials are always challenging, and clinical approaches and the needs for supportive services continue to evolve.
The European Clinical Trial Regulation 536/2014 (CTR) will be coming into full effect in 2022, and will significantly change how companies conduct their trials.
WHITEPAPER: IRT systems can be a double-edged sword. Set up properly, it can make your clinical supply strategy a breeze to execute. Set up improperly, it can apply additional pressure and stress to a sponsor’s resupply execution
WHITE PAPER: When pharmaceutical and biopharmaceutical companies engage in new product development, there is a historical tendency to focus on the immediate needs of the clinical phase. As a result, many commercialization-related decisions...
When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?
Start your PCI experience today.Your bridge between life-changing therapies and patients.
